Status: Planned First registered on: 15/07/2016
Last updated on: 04/02/2020
1. Study identification
EU PAS Register NumberEUPAS14111
Official titleImpact of Optimum Patient Care’s clinical review service
Study title acronymImpact of OPC
Study typeObservational study
Brief description of the studyHistorical cohort study evaluating the impact of a remote annual asthma clinical review service on high risk asthma patients in a UK primary care setting. Optimum Patient Care (OPC) is a social enterprise company whose aim is to improve patient outcomes in respiratory medicine through continuous audit and feedback to practices at a practice and individual patient level. OPC offers a free and unique remote clinical review service to support management of patients in primary care, using the company’s bespoke software tools. OPC provides practices with patient-specific reports including suggestions for interventions in accord with current asthma guidelines. These recommendations include identification of patients at high-risk of exacerbations and of patients who are seemingly on inappropriate medication and require urgent attention. The purpose of this study is to evaluate, for the first time, the impact that OPC’s review service has on patients’ primary care utilisation, treatment and asthma exacerbation frequency. The analysis will focus on patients who are deemed high risk based on their exacerbation history. The data extracted from practices by OPC enters their service database and is used to create patient-specific recommendations to the practice. It is also anonymized for use in respiratory research. This database, cleared of all patient identifiable information, is called the Optimum Patient Care Research Database (OPCRD) and will be used in this study.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsOPRI Pte Ltd
Department/Research groupResearch in Real Life Ltd
Organisation/affiliationOPRI Pte Ltd
Website/Homepagehttps://opri.sg/
Details of (Primary) lead investigator
Title Professor
Last name Price
First name David
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/03/2016
Start date of data collection01/08/2016
Start date of data analysis01/09/2016
Date of interim report, if expected
Date of final study report26/02/2021
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherOptimum Patient Care100
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name David
First name Price
Address line 15 Coles Lane
Address line 2Oakington 
Address line 3 
CityCambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom
Phone number (incl. country code)6582822594 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg
Public Enquiries
Title Professor 
Last name David 
First name Price 
Address line 15 Coles Lane 
Address line 2Oakington 
Address line 3 
CityCambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom 
Phone number (incl. country code)6582822594 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg 
Top